Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 1CNS 1

Conditions

Carcinoma, Non-Small-Cell Lung 6Neoplasms 5Small Cell Lung Carcinoma 3Neoplasm Metastasis 3Nasopharyngeal Carcinoma 2Esophageal Neoplasms 2Colorectal Neoplasms 2Breast Neoplasms 2Advanced Cancer 2Triple Negative Breast Neoplasms 1Thyroid Neoplasms 1Stomach Neoplasms 1Stereotactic Body Radiation Therapy 1Sarcoma 1Recurrence 1Platinum-resistant Recurrent Clear Cell Ovarian Cancer 1Pheochromocytoma 1Paraganglioma, Extra-Adrenal 1Paraganglioma 1Pancreatic Neoplasms 1NSCLC 1Lung Neoplasms 1Esophageal Squamous Cell Carcinoma 1Colonic Neoplasms 1Carcinoma, Medullary 1Brain Neoplasms 1Advanced Solid Tumors 1Advanced Malignancy 1Advanced Endometrial Cancer 1Adenocarcinoma of Lung 1

Interventions

lenvatinib 2Temozolomide 2temsirolimus 1cabozantinib 1anlotinib 1Vorinostat 1Vinorelbine 1Sirolimus 1Restraint, Physical 1Everolimus 1Absorptiometry, Photon 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Paraganglioma, Extra-Adrenal × anlotinib × Clear all
NCT04860700 2024-06-12

The Efficacy and Safety of Anlotinib in Patients With Metastatic Pheochromocytoma or Paraganglioma

Peking Union Medical College Hospital

Phase 2 Completed
27 enrolled
CNSEndocrine

Neoplasm Metastasis, Paraganglioma, Paraganglioma, Extra-Adrenal, Pheochromocytoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡